Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
74.34
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
November 05, 2021
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing...
Via
Benzinga
Exposures
COVID-19
Product Safety
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
November 02, 2021
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...
Via
Benzinga
Healthcare Stocks Subject to Government Policy
November 02, 2021
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
This Cheap Stock Is Paying An Unusually High Yield
November 01, 2021
Gilead has increased their dividend for seven consecutive years. The three-year dividend growth rate of 9.4% shows the level of growth they’re capable of delivering.
Via
Talk Markets
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
October 28, 2021
Gilead Sciences came out with quarterly earnings of $2.65 per share.
Via
Talk Markets
5 M&A Stocks to Watch as Goldman Calls for a Big Jump in Deals
November 01, 2021
Goldman Sachs predicts the Democrats' new tax plan could yield positive results for M&A-focused companies. Here are the M&A stocks to watch.
Via
InvestorPlace
Gilead Sciences (GILD) Q3 2021 Earnings Call Transcript
October 29, 2021
GILD earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...
Via
Benzinga
GILD: Is This Biotech’s 4.2% Yield Healthy?
October 27, 2021
Gilead’s free cash flow hit a recent peak of $19.5 billion in 2015 before falling each of the next two years, settling around $7.5 billion in 2018.
Via
Talk Markets
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Gilead Trims Non-COVID Product Sales Outlook, Though Q3 Earnings Beat Street Estimates
October 29, 2021
Gilead Sciences Inc (NASDAQ: GILD) posted higher-than-expected Q3 earnings on strong demand for its COVID-19 antiviral treatment. Adjusted EPS increased 26% Y/Y to...
Via
Benzinga
Topics
Earnings
Exposures
COVID-19
Financial
Recap: Gilead Sciences Q3 Earnings
October 28, 2021
Gilead Sciences (NASDAQ:GILD) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Gilead Crushes Quarterly Forecasts and Raises Outlook For 2021; But Shares Dip
October 28, 2021
Gilead beat Wall Street's quarterly forecasts and raised its outlook for 2021.
Via
Investor's Business Daily
Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral
October 28, 2021
Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a...
Via
Benzinga
Gilead Sciences Earnings Preview
October 27, 2021
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
October 27, 2021
It's much too early to count these companies out.
Via
The Motley Fool
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
October 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M...
Via
Benzinga
2 High-Yielding Stocks You Can Buy and Hold for Years
October 23, 2021
They pay more than double what the average S&P 500 stock yields.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
October 23, 2021
Signs point to yes, but it's still early in the game.
Via
The Motley Fool
Exposures
COVID-19
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
October 18, 2021
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...
Via
Talk Markets
Crispr: A Fallen Angel In Gene Editing
October 16, 2021
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...
Via
Talk Markets
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
October 15, 2021
Companies working on sorely needed Covid treatments are innovating to keep up.
Via
Investor's Business Daily
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
October 14, 2021
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based...
Via
Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
October 12, 2021
Crispr is planning to begin a registrational test in the first quarter of 2022.
Via
Investor's Business Daily
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
October 12, 2021
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, molnupiravir. As vaccines are requiring a third booster...
Via
Benzinga
Exposures
COVID-19
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
October 11, 2021
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB...
Via
Talk Markets
Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
October 06, 2021
A new study shows it is highly effective in preventing deaths if taken early.
Via
The Motley Fool
Topics
Death
Exposures
COVID-19
Death
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
October 05, 2021
Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19....
Via
Benzinga
Exposures
COVID-19
Tesla and Merck Give Investors Some Hope
October 04, 2021
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate...
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.